Interdisciplinarity
By Jonathan Kahn, Biopolitical Times guest contributor
| 01. 24. 2011
In 2009, the director of the National Science Foundation gave a key note
address at an interdisciplinary conference on synthetic biology
sponsored by the National Academies. The director opened with the
following joke:
“A synthetic biologist and a social scientist await death
at the hands of an executioner. The executioner asks the social
scientist if he has a final wish. Yes, he says, I have some new findings
on the societal and ethical dimensions of synthetic biology and I want
to present them to the scientific community before I die. The
executioner then turns to the synthetic biologist and asks if she has a
final wish. Yes, she said, just shoot me before I have to listen to that
lecture.”
It’s a good joke. I have sat through many lectures over the years
that make me sympathize with the synthetic biologist. Lest he offend
anyone in the audience, the director quickly followed the joke with a
disclaimer that certainly no one in the present audience harbored such
sentiments. Nonetheless, the joke is instructive on several levels.
Synthetic
biology is merely...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...